With results possibly out in approx 6-8months, if the results of the phase 2 results are positive, what should the likely MC be for parkinsonian disorder based on previous history in drug development?
I know the dilution is significant right now, but would love to hear feedback from experienced posters.
I recall doing this exercise years ago with PBT2 and the Alzheimers market but a lot has changed since then in the Big Pharma space.
Value of company post Positive phase 2 trial results
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $130.5K | 26.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 106 | 98813145 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13634538 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |